Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06861439 · ClinicalTrials.gov registry record · Phase 4
GLP-1s to Enhance Lasting Optimal Weight
A Phase 4 study of Obesity, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06861439 is a Phase 4 study of Obesity that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 40 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06861439, a Phase 4 study of Obesity, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in person or video conference, attend group intervention sessions twice a month via video conference, weigh daily with a study-provided smart scale, keep a record of all foods and beverages consumed, and use a study-provided activity tracker to keep track of daily step counts.
Conditions Studied
Interventions
- DRUG Tirzepatide
Study Locations (1)
North Carolina
- Wake Forest University Health Sciences - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-07-07 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06861439
The ClinicalTrials.gov registry entry for NCT06861439 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Tirzepatide is the first listed.
NCT06861439 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06861439 about?
NCT06861439 is a clinical study titled "GLP-1s to Enhance Lasting Optimal Weight". The goal of this study is to examine how tirzepatide affects body composition, bone health, and physical performance in older adults over a nine-month period. Participants will take tirzepatide weekly, have clinic visits every 4 weeks, meet study doctor and registered dietitian every 4 weeks in pers...
What is the current status of trial NCT06861439?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-07-07. Estimated completion is 2026-12-31.
What conditions does trial NCT06861439 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06861439?
The interventions under investigation include: Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06861439?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06861439 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.